- Home
- NNY vs LCTX Comparison
NNY vs LCTX Comparison
Compare NNY & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- LCTX
- Stock Information
- Founded
- NNY 1987
- LCTX 1990
- Country
- NNY United States
- LCTX United States
- Employees
- NNY N/A
- LCTX N/A
- Industry
- NNY Investment Managers
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNY Finance
- LCTX Health Care
- Exchange
- NNY Nasdaq
- LCTX Nasdaq
- Market Cap
- NNY 156.4M
- LCTX 127.7M
- IPO Year
- NNY N/A
- LCTX N/A
- Fundamental
- Price
- NNY $8.29
- LCTX $0.68
- Analyst Decision
- NNY
- LCTX Strong Buy
- Analyst Count
- NNY 0
- LCTX 4
- Target Price
- NNY N/A
- LCTX $4.50
- AVG Volume (30 Days)
- NNY 50.9K
- LCTX 1.2M
- Earning Date
- NNY 01-01-0001
- LCTX 03-06-2025
- Dividend Yield
- NNY 4.04%
- LCTX N/A
- EPS Growth
- NNY N/A
- LCTX N/A
- EPS
- NNY N/A
- LCTX N/A
- Revenue
- NNY N/A
- LCTX $8,719,000.00
- Revenue This Year
- NNY N/A
- LCTX N/A
- Revenue Next Year
- NNY N/A
- LCTX $41.15
- P/E Ratio
- NNY N/A
- LCTX N/A
- Revenue Growth
- NNY N/A
- LCTX N/A
- 52 Week Low
- NNY $7.58
- LCTX $0.48
- 52 Week High
- NNY $8.87
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- NNY 57.76
- LCTX 53.39
- Support Level
- NNY $8.26
- LCTX $0.58
- Resistance Level
- NNY $8.34
- LCTX $0.73
- Average True Range (ATR)
- NNY 0.08
- LCTX 0.05
- MACD
- NNY 0.00
- LCTX 0.00
- Stochastic Oscillator
- NNY 60.71
- LCTX 50.67
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.